Free Trial
NASDAQ:ABVX

Abivax Q3 2025 Earnings Results & Report

Abivax logo
$83.61 -3.97 (-4.53%)
Closing price 04:00 PM Eastern
Extended Trading
$83.52 -0.09 (-0.11%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abivax reported Q3 2025 earnings on December 15, 2025. The company reported EPS of -$2.46, while revenue was -$4.92 million.

Earnings Announcement Details

Quarter
Q3 2025
Time
After Market Closes
Conference Call
11:45 AM ET

Abivax EPS Results

Actual EPS
-$2.46
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 4 quarters

Abivax Revenue Results

Actual Revenue
-$4.92 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Abivax's Q3 2026 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Monday, December 14, 2026 at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Abivax Q3 2025 Earnings FAQ

Abivax (NASDAQ:ABVX) reported earnings of -$2.46 per share for Q3 2025. The report was announced on Monday, December 15, 2025.

Abivax reported revenue of -$4.92 million for Q3 2025.

Abivax's next earnings date is estimated for Monday, December 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for Abivax on the company's earnings history page.

Abivax Earnings Headlines

Abivax to Participate in Upcoming Fall Investor Conferences
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Abivax SA ADR ABVX
See More Abivax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Abivax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abivax and other key companies, straight to your email.

About Abivax

Abivax (NASDAQ:ABVX) is a clinical-stage biopharmaceutical company headquartered in Paris, France. It develops treatments for chronic inflammatory diseases, with a focus on therapies that regulate the body’s immune response.

The company’s lead candidate, obefazimod (formerly known as ABX464), is an oral small molecule being studied for ulcerative colitis and other inflammatory conditions. It is designed to increase production of miR-124, a molecule involved in regulating inflammation.

Founded in 2013, Abivax conducts clinical development internationally. Marc de Garidel has served as the company’s chief executive officer.

View Abivax Profile